Genocea Biosciences Inc (GNCA) stock is down 8.62% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With GNCA Stock Today?
Genocea Biosciences Inc (GNCA) stock has fallen -6.29% while the S&P 500 has risen 1.02% as of 12:14 PM on Thursday, May 13. GNCA has fallen -$0.14 from the previous closing price of $2.26 on volume of 316,680 shares. Over the past year the S&P 500 is up 43.01% while GNCA has fallen -21.48%. GNCA lost -$0.97 per share in the over the last 12 months.
To screen for more stocks like Genocea Biosciences Inc click here.
More About Genocea Biosciences Inc
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Click Here to get the full Stock Score Report on Genocea Biosciences Inc (GNCA) Stock.
